Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://ncbi.nlm.nih.gov/pubmed/26466856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1106658
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados